1stOncology™: Cancer Intelligence Service – Page 12301 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

First Patient in Treatment for RhoVac’s Clinical Phase II Study in Finland

On March 3, 2020 RhoVac AB ("RhoVac") reported, on 3rd March 2020, that the first patient in Finland has started treatment in the company’s clinical phase IIb study in prostate cancer, a study entitled RhoVac-002 ("BRaVac") (Press release, RhoVac, MAR 3, 2020, View Source [SID1234555154]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The first patient in Finland has now started treatment in the clinical study, called BRaVac. This clinical trial phase IIb-study is a randomized, placebo-controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative treatment. The phase IIb study is an international, multicenter study, which will recruit over 175 patients in six European countries and the US. RhoVac has previously received approval to start phase IIb clinical trials in Denmark, Finland, Belgium, Germany and the US, and is awaiting final approval from the ethical committees in Sweden and the UK. The ambition is that all patients should be recruited by end of Q3 2020. The results report on active treatment part of the study is expected in H2 2021.

China Biologic Products to Report Fourth Quarter and Fiscal Year 2019 Financial Results

On March 3, 2020 China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, reported that the Company plans to release its fourth quarter and fiscal year 2019 financial results on Thursday, March 12, 2020 after the market closes (Press release, China Biologic Products, MAR 3, 2020, View Source [SID1234555153]).

The Company’s management will hold a conference call at 7:30 a.m. ET on Friday, March 13, 2020, which is 7:30 p.m. Beijing Time on March 13, 2020, to discuss fourth quarter and fiscal year 2019 results. Listeners may access the call by dialing:

US:

1 888 346 8982

International:

1 412 902 4272

Hong Kong:

800 905945

Mainland China:

4001 201203

A telephone replay will be available one hour after the conclusion of the conference call through March 20, 2020. The dial-in details are:

US:

1 877 344 7529

International:

1 412 317 0088

Passcode:

10139946

A live and archived webcast of the conference call will be available through the Company’s investor relations website at View Source

NCCN and AstraZeneca Announce Projects to Explore Quality Improvements in Lung Cancer

On March 3, 2020 The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) reported three research projects selected to receive funding to improve healthcare provider performance and/or healthcare quality, focusing on enhancing patient care and outcomes for people with advanced non-small cell lung cancer (NSCLC) (Press release, NCCN, MAR 3, 2020, View Source [SID1234555152]). The designated projects will be funded through a collaboration with AstraZeneca, a global, science-led biopharmaceutical company.

"Lung cancer is still the number one cause of cancer death in the United States," said Wui-Jin Koh, MD, Chief Medical Officer, NCCN. "We’ve seen rapid and robust progress in treating this cancer recently, and it’s having a significant impact on reducing mortality. Now we want to make it easier for medical practices to implement these innovations and make sure they’re reaching every patient who could benefit from them. These projects will hopefully serve as sustainable models for promoting system efficiency and enhancing patient outcomes and satisfaction."

The selected projects are:

Developing a PREcision meDICine Thoracic (PREDICT) Service in a Large Practice Network: Focus on Implementation, Physician and Patient Impact
Debora Bruno, MD, MS, and Navid Sadri, MD, PhD, University Hospitals – Seidman Cancer Center
Randomized Trial of a Supportive Care Mobile Application (App) to Improve Symptoms, Coping, and Quality of Life in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Joseph Greer, PhD, and Jennifer Temel, MD, Massachusetts General Hospital Cancer Center
System-wide Integration of Plasma-based Next Generation Sequencing into Clinical Pathways for Detection of NCCN Recommended Biomarkers to Improve the Management of Patients with Metastatic Non-squamous NSCLC
Charu Aggarwal, MD, Hospital of the University of Pennsylvania
"AstraZeneca is committed to eliminating cancer as a cause of death," said Adrian Kilcoyne, MD, VP, US Medical Affairs, AstraZeneca. "We cannot do this through innovative medicines alone, we must also be active partners in improving the quality of cancer care for patients. We are pleased to partner with NCCN in support of this important work."

The research projects will begin in the third quarter of 2020 and continue for two years. The results from the funded projects will be disseminated upon completion to improve delivery of cancer care in other practices.

The NCCN ORP fosters innovation and knowledge discovery that improves the lives of people with cancer and supports preclinical, translational, clinical research and quality improvement projects in oncology at NCCN Member Institutions. In an effort to improve collaboration in cancer research, the NCCN ORP also maintains a shared resources website and an informed consent database. For more information, visit NCCN.org/orp.

Natera to Participate in Upcoming Investor Conferences

On March 3, 2020 Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, reported that it will webcast live presentations at the Cowen and Company 40th Annual Health Care Conference in Boston on Wednesday, March 4, 2020 at 8:20 a.m. PT (11:20 a.m. ET) and at the Barclays Global Healthcare Conference in Miami on Wednesday, March 11, 2020 at 12:20 p.m. PT (3:20 p.m. ET) (Press release, Natera, MAR 3, 2020, View Source [SID1234555151]).

Mike Brophy, Chief Financial Officer, will be presenting at both conferences, where he will provide an overview of Natera and discuss recent business activities.

Cowen and Company Health Care Conference Details:

Date:

Wednesday, March 4, 2020

Time:

8:20 a.m. PT (11:20 a.m. ET)

Live Webcast:

http://wsw.com/webcast/cowen57/ntra/

Barclays Global Healthcare Conference Details:

Date:

Wednesday, March 11, 2020

Time:

12:20 p.m. PT (3:20 p.m. ET)

Live Webcast:

https://cc.talkpoint.com/barc002/031020a_js/?entity=47_WGWC0EN

Replays of both webcasts will be archived and available at investor.natera.com.

Spherix Announces Pricing of $7.5 Million Public Offering

On March 3, 2020 Spherix Incorporated (SPEX) ("Spherix" or the "Company"), a technology development company committed to the fostering of innovative ideas, reported that it has priced a public offering of an aggregate of 7,142,858 shares of common stock (or common stock equivalents) of the Company and warrants to purchase up to 7,142,858 shares of common stock. Each share of common stock (or common stock equivalent) is being sold together with one warrant to purchase one share of common stock, at a public offering price of $1.05 per share and accompanying warrant (Press release, Spherix, MAR 3, 2020, View Source [SID1234555150]). The shares of common stock (or common stock equivalents) and the accompanying warrants are being sold together in this offering, but will be issued separately and will be immediately separable upon issuance. The warrants are exercisable immediately and expire five years from the date of issuance. Each warrant has an exercise price of $1.05.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds to Spherix from this offering are expected to be approximately $7.5 million, before deducting the placement agent’s fees and other estimated offering expenses payable by Spherix. This offering is expected to close on or about March 5, 2020, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The offering is being conducted pursuant to the registration statement on Form S-1 (File No. 333-236199), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC") on March 3, 2020. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at View Source Electronic copies of the final prospectus relating to this offering, when available, may be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at [email protected] or by telephone at 646-975-6996. Before investing in this offering, interested parties should read in their entirety the registration statement that the Company has filed with the SEC, which provides additional information about the Company and this offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.